Tarsus Pharmaceuticals, Inc. TARS Commercial and Sales Milestones — Maximum milestone payments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept tars:CollaborativeArrangementMaximumMilestonePayment.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s commercial and sales milestones — maximum milestone payments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s commercial and sales milestones — maximum milestone payments?
- Tarsus Pharmaceuticals, Inc. (TARS) reported commercial and sales milestones — maximum milestone payments of $77M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s commercial and sales milestones — maximum milestone payments changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s commercial and sales milestones — maximum milestone payments decreased by 0.0% year-over-year, from $77M to $77M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s commercial and sales milestones — maximum milestone payments?
- Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s commercial and sales milestones — maximum milestone payments has grown at a -0.6% compound annual growth rate (CAGR), from $312M to $308M.
- What does commercial and sales milestones — maximum milestone payments mean?
- This metric quantifies the total potential future milestone payments that the company could receive upon the successful achievement of predefined commercial or sales-based performance targets. It serves as an indicator of the total upside potential embedded in existing licensing or collaboration agreements. Monitoring this figure provides insight into the long-term value capture expected from the commercialization of the company's product portfolio.